Search results
Results from the WOW.Com Content Network
284.9 Aplastic anemia unspecified; 285 Other and unspecified anemias. 285.0 Sideroblastic anemia; 285.1 Acute posthemorrhagic anemia; 285.2 Anemia in chronic illness. 285.21 Anemia in chronic kidney disease; 285.22 Anemia in neoplastic disease; 285.29 Anemia of other chronic illness; 285.3 Antineoplastic chemotherapy induced anemia; 285.8 Other ...
The International Classification of Diseases for Oncology (ICD-O) is a domain-specific extension of the International Statistical Classification of Diseases and Related Health Problems for tumor diseases.
An anemia is a decrease in number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. [2] [3] However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency.
The treatments for cytopenia vary depending on the type of cytopenia. The treatment for anemia is rest and a diet consisting of high iron foods. Medication can also be used such as: [citation needed] Epoetin alfa, a synthetic erythropoietin that stimulates stem cells to produce red blood cells.
Myelophthisic anemia (or myelophthisis) is a severe type of anemia found in some people with diseases that affect the bone marrow. Myelophthisis refers to the displacement of hemopoietic bone-marrow tissue [1] by fibrosis, tumors, or granulomas. The word comes from the roots myelo-, which refers to bone marrow, and phthisis, shrinkage or atrophy.
Diamond-Blackfan Anemia is an example of a congenital bone marrow failure syndrome that primarily affects red blood cell production. In DBA, the erythroid cell lineage is more susceptible to cell death due to abnormal ribosome function. [4] This leads to a reduced population of red blood cell precursors and a resulting reticulocytopenia and anemia.
Due to dangers associated with using ESAs, their use should be limited to the clinic where anemic patients are boosted back to normal hemoglobin levels (as opposed to going above the normal levels for performance advantage, leading to an increased risk of death). [citation needed]
Aplastic anemia is a rare, noncancerous disorder in which the blood marrow is unable to adequately produce blood cells required for survival. [44] [45] It is estimated that the incidence of aplastic anemia is 0.7–4.1 cases per million people worldwide, with the prevalence between men and women being approximately equal. [46]